Endocyte, Inc. is a West Lafayette, IN-based development-stage biopharmaceutical company focused on bringing targeted therapies for the treatment of cancer and inflammatory diseases to market.
The company’s pipeline candidate 177Lu-PSMA-617 is a first-in-class radioligand and therapeutic (RLT) that targets prostate-specific membrane antigen (PSMA). The company acquired exclusive worldwide rights to develop and commercialize 177Lu-PSMA-617 from ABX GmbH in October 2017. The candidate represents a more than $1 billion market opportunity and its development is now the main priority of the company.
Currently, the company plans to focus on its most promising programs - lutetium PSMA-617 radioligand therapy and prostate cancer, and CAR T-cell small-molecule drug conjugates (SMDC) adaptor platform.
Endocyte’s earnings track record has been mixed so far. Over the four trailing quarters, the company has posted an average positive earnings surprise of 1.40%.
Currently, Endocyte has a Zacks Rank #2 (Buy), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Endocyte’s second-quarter 2018 loss was narrower-than-expected. The company posted a loss of 17 cents per share narrower than the consensus estimate of a loss of 19 cents.
Key Stats: The company continued to execute rapidly on its strategy of initiating the phase III VISION study of 177Lu-PSMA-617 and securing a long-term commercial supply agreement for no-carrier added lutetium, which could support treatment of a potentially large patient population if approved. The company also expects to file an investigational new drug (IND) application for EC17/CAR T-cell therapy in patients with osteosarcoma in the fourth quarter of 2018.
Share Price Impact: The shares were up almost 2.8% in pre-market trading.
Check back later for our full write up on ECYT earnings report later!
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%. And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Image: Bigstock
Endocyte (ECYT) Posts Narrower than Expected Loss in Q2
Endocyte, Inc. is a West Lafayette, IN-based development-stage biopharmaceutical company focused on bringing targeted therapies for the treatment of cancer and inflammatory diseases to market.
The company’s pipeline candidate 177Lu-PSMA-617 is a first-in-class radioligand and therapeutic (RLT) that targets prostate-specific membrane antigen (PSMA). The company acquired exclusive worldwide rights to develop and commercialize 177Lu-PSMA-617 from ABX GmbH in October 2017. The candidate represents a more than $1 billion market opportunity and its development is now the main priority of the company.
Currently, the company plans to focus on its most promising programs - lutetium PSMA-617 radioligand therapy and prostate cancer, and CAR T-cell small-molecule drug conjugates (SMDC) adaptor platform.
Endocyte’s earnings track record has been mixed so far. Over the four trailing quarters, the company has posted an average positive earnings surprise of 1.40%.
Currently, Endocyte has a Zacks Rank #2 (Buy), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Endocyte’s second-quarter 2018 loss was narrower-than-expected. The company posted a loss of 17 cents per share narrower than the consensus estimate of a loss of 19 cents.
Key Stats: The company continued to execute rapidly on its strategy of initiating the phase III VISION study of 177Lu-PSMA-617 and securing a long-term commercial supply agreement for no-carrier added lutetium, which could support treatment of a potentially large patient population if approved. The company also expects to file an investigational new drug (IND) application for EC17/CAR T-cell therapy in patients with osteosarcoma in the fourth quarter of 2018.
Share Price Impact: The shares were up almost 2.8% in pre-market trading.
Check back later for our full write up on ECYT earnings report later!
Endocyte, Inc. Price and Consensus
Endocyte, Inc. Price and Consensus | Endocyte, Inc. Quote
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%. And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>